[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-low-back-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-low-back-pain":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,94,0,25,[9,40,57,88,116,142,165,185,207,244,272,295,314,340,369,391,412,436,468,489,525,557,584,611,642],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100652703","the-prediction-of-clinical-outcome-using-the-serum-bdnf-level-100652703",false,"NCT07776379","The Prediction of Clinical Outcome Using the Serum BDNF Level","Inclusion Criteria:\n\n* Chronic low back pain patients with or without leg pain due to disc degeneration or spinal stenosis\n* Patients who have MRI\n\nExclusion Criteria:\n\n* Secondary low back pain (spine fracture, infection, tumor)\n* recent history of spine surgery\n* systemic inflammatory disease (rheumatoid arthritis, SLE, ankylosing spondylitis)\n* peripheral neuropathy or central nervous system injury\n* fibromyalgia\n* drugs which can affect the serum BDNF level (anti depressant, anti parkinsonian drug, acetylcholinesterase inhibitor, anti psychotics)","ALL","20 Years","80 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","Low back pain (LBP) is one of the most commonly observed conditions in patients over the age of 50 and imposes a substantial socioeconomic burden. Degenerative disc disease is one of the most frequent and important causes of this pain. Progressive disc degeneration is characterized by a decline in disc cell number and degradation of the extracellular matrix. Loss of nucleus pulposus (NP) volume and hydration, together with fissure formation within the annulus fibrosus (AF), develop gradually with aging and ultimately lead to functional impairment. Disc degeneration can result from multiple factors, including aging, obesity, genetic predisposition, degeneration of the multifidus and psoas muscles, osteoporosis, inflammation, and oxidative stress. The intervertebral disc consists of the gel-like nucleus pulposus (NP) at its center, the surrounding annulus fibrosus (AF), and the cartilaginous endplates above and below. Because the disc is an avascular structure, its capacity for self-repair is markedly limited.\n\nErector spinae plane block (ESPB) is a treatment option that can be performed in the outpatient setting for patients with such low back pain. ESPB was first described in 2016 and is a type of interfascial plane block. Unlike neuraxial blocks, it offers the advantage of being both technically straightforward and highly safe. Recent studies indicate that ESPB is increasingly applied to patients with post-spinal-surgery pain or chronic low back pain.\n\nBrain-derived neurotrophic factor (BDNF) is a neurotrophin that regulates neuronal survival, differentiation, and synaptic plasticity within the central nervous system. In the context of pain, BDNF released from primary afferent nociceptors and spinal dorsal horn microglia has been implicated in central sensitization, a key mechanism underlying the transition from acute to chronic pain. Circulating BDNF concentrations have been reported to be associated with pain intensity, disability, and cortical\u002Fcorticomotor plasticity in patients with chronic low back pain, and some studies have found serum BDNF levels to be significantly elevated in discogenic chronic low back pain compared with controls, while others report reduced circulating BDNF in chronic pain populations - suggesting that the relationship between BDNF and pain chronicity may vary by pain phenotype and warrants further clarification. Because BDNF reflects neuroplastic changes that accompany the development and persistence of chronic pain, it has been proposed as a potential predictor of treatment response. However, no study to date has directly examined whether serum BDNF concentration can predict the clinical outcome of ESPB in patients with low back pain.",[25,26],"Chronic Low Back Pain","Brain Derived Neurotrophic Factor Level","RECRUITING","2026-08-19",{"date":30,"type":31},"2026-08-21","ACTUAL",{"date":33,"type":31},"2026-08-13",{"date":35,"type":21},"2028-05-30",{"name":37,"class":38},"Keimyung University Dongsan Medical Center","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":54,"leadSponsor":56,"locationsCount":39},"100652643","study-of-correlation-between-the-level-of-intradiscal-periostin-expression-and-pfirrmann-grading-100652643","NCT07776366","Study of Correlation Between the Level of Intradiscal Periostin Expression and Pfirrmann Grading","Study of Correlation Between the Level of Intradiscal Periostin Expression and Pfirrmann Grading.","Inclusion Criteria:\n\n* lumbar disc herniation\n* lumbar spinal canal stenosis\n* patients who have MRI\n\nExclusion Criteria:\n\n* allergic disease\n* allergic rhinitis\n* asthma\n* atopic dermatitis\n* chronic sinusitis\n* history of cancer\n* fracture within 6 months\n* severe osteoporosis\n* knee osteoarthritis\n* hip osteoarthritis\n* spinal surgery within 6 months\n* myocardiac infarction\n* heart failure\n* liver cirrhosis",{"count":48,"type":21},20,"Intervertebral disc degeneration (IVDD) is a well-recognized musculoskeletal condition that imposes a substantial socioeconomic burden and is an important cause of low back pain. IVDD can result from a variety of factors, including aging, obesity, genetic predisposition, degeneration of the multifidus and psoas muscles, osteoporosis, inflammation, and oxidative stress. The intervertebral disc (IVD) within the spine is composed of a gel-like nucleus pulposus (NP) at its center, a surrounding annulus fibrosus (AF), and cartilaginous endplates above and below. The NP and AF produce a water-rich extracellular matrix (ECM), which contributes to normal functioning of the spinal column.\n\nVarious internal and external stimuli cause dysfunction of the NP and AF, and excessive metabolic activity of the endplates leads to endplate degeneration and calcification, ultimately resulting in disc degeneration. In addition to aging and mechanical overload, increased oxidative stress and inflammatory cytokine release further accelerate IVDD.\n\nPeriostin is a component of the ECM that is associated with mechanical stress, inflammation, and aging, and has been closely linked to the development and progression of IVDD. Periostin binds to ECM molecules within the IVD and is involved in disc maintenance and repair; however, excessive ECM turnover induces and accelerates disc degeneration. Periostin affects IVD degeneration through pathways related to mechanical stress and inflammation, and serum periostin levels have been reported to be elevated in patients with more advanced disc degeneration. A recent study demonstrated a strong correlation between serum periostin concentration and the Pfirrmann grading system. However, measuring periostin concentration through blood sampling has limitations, as serum periostin levels can also increase similarly in patients with a history of head and neck cancer or allergic disease. Therefore, it is necessary to directly assess the degree of periostin expression within the intervertebral disc itself and to determine whether it shows a meaningful correlation with the Pfirrmann grading system. In addition, periostin is known to be more abundant in the AF than in the NP, but this has not previously been demonstrated through actual staining of disc tissue; this study therefore aims to compare the degree of periostin expression between the NP and AF using immunohistochemical staining.\n\nPfirrmann et al. developed a reliable, MRI-based grading system that is the most commonly used method for evaluating IVDD. The Pfirrmann grading system is based on analysis of T2-weighted MR sagittal images of the IVD, incorporating disc homogeneity, morphology, the distinction between the AF and NP boundary, T2 signal intensity, and disc height.",[25,51],"Spinal Stenosis Lumbar",{"date":30,"type":31},{"date":33,"type":31},{"date":55,"type":21},"2027-08-30",{"name":37,"class":38},{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":39},"100643683","prospective-case-series-evaluating-6-month-and-12-month-outcomes-after-cryoneurolysis-for-chronic-pain-100643683","NCT07639060","Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain","Inclusion Criteria:\n\n* Diagnosis of chronic pain (generally pain duration of at least 3-6 months) localized to an anatomical region appropriate for cryoneurolysis as determined by the treating physician.\n* Planned cryoneurolysis procedure as part of standard clinical care.\n* Ability to provide written informed consent.\n* Ability and willingness to complete baseline and follow-up questionnaires.\n\nExclusion Criteria:\n\n* Cryoneurolysis performed as part of a separate investigational trial in which data sharing is not permitted.\n* Active infection or other clinical contraindication to the procedure as determined by the treating clinician.\n* Life expectancy of less than 12 months in the judgment of the treating clinician.\n* Any condition that, in the investigator's opinion, would interfere with study participation or completion of follow-up, such as severe psychiatric instability or active substance use that precludes reliable follow-up","18 Years",{"count":65,"type":21},80,"To prospectively describe patient-centered and health utilization outcomes through 12 months after cryoneurolysis performed as routine clinical care for chronic pain at Yale.",[68,69,70,71,72,73,74,25,75,76,77,78,79,80],"Chronic Pain","PERIPHERAL NEUROPATHY","Occipital Neuralgia","Chronic Hip Pain","Hip Osteoarthritis","Knee Osteoarthritis","Spasticity","Lumbar Spondylosis","Cervical Spondylosis","Shoulder Arthritis","Causalgia","Chronic Pain Syndrome","Chronic Neck Pain",{"date":30,"type":31},{"date":83,"type":31},"2026-06-20",{"date":85,"type":21},"2028-07",{"name":87,"class":38},"Yale University",{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100579231","telerehabilitation-for-patients-with-chronic-low-back-pain-teleback-clinical-trial-100579231","NCT06821607","Telerehabilitation for Patients With Chronic Low Back Pain (TeleBACK Clinical Trial)","TeleBACK","Inclusion Criteria:\n\n* Primary care visit in the past 90 days with an LBP-related ICD-10 diagnosis.\n* At least moderate levels of pain and disability requiring Oswestry score ≥24% and average pain rating ≥ 4\u002F10 points.\n* Meets NIH Task Force2 definition of chronic LBP based on two questions: 1) How long has LBP has been an ongoing problem? and 2) How often has LBP been an ongoing problem over the past 6 months? A response of greater than 3 months to question 1, and \"at least half the days in the past 6 months\" to question 2 is required to satisfy the NIH definition of chronic LBP.\n* Can speak and understand English or Spanish (Utah sites only).\n\nExclusion Criteria:\n\n* Recent history (last 6 months) of lumbar spine surgery.\n* Possible non-musculoskeletal cause for low back pain symptoms (e.g., pregnancy).\n* Evidence of serious pathology as a cause of LBP including neoplasm, inflammatory disease (e.g., ankylosing spondylitis), vertebral osteomyelitis, etc.\n* Neurological disorder resulting in severe movement disorder, or schizophrenia or other psychotic disorder.\n* Knowingly pregnant","64 Years",{"count":97,"type":21},1000,"INTERVENTIONAL",[100],"NA","The investigators will conduct a prospective, randomized, clinical trial addressing key questions to understanding the effectiveness of telerehabilitation (physical therapy delivered via video-visits) and in-clinic physical therapy for patients with chronic low back pain (LBP). The investigators also seek to understand how patients engage with both care options and how these treatment options influence other LBP-related healthcare utilization.\n\nThe investigators will explore implementation outcomes using a mixed methods approach consisting of electronic surveys and semi-structured interviews with patients, physical therapists, practice managers, and outpatient services administration focusing on perceived quality and impact on barriers to care. The investigators will enroll 1000 patients with chronic LBP seeking outpatient care at the healthcare systems in Maryland (Johns Hopkins Medicine (JHM)) and Utah (University of Utah (UU) and Intermountain Healthcare (IHC)). Eligible patients will provide informed consent and be randomized to receive telerehabilitation or in-clinic physical therapy delivered by a trained physical therapist. Primary effectiveness outcome is the difference in change in LBP-related disability (Oswestry Disability Index) after 8 weeks of treatment.",[25],[104,105,106,107],"chronic low back pain","physical therapy","telehealth","telerehabilitation",{"date":30,"type":31},{"date":110,"type":31},"2025-04-01",{"date":112,"type":21},"2030-05-01",{"name":114,"class":38},"Johns Hopkins University",3,{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":98,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100501620","lifestyle-intervention-in-overweightobese-chronic-low-back-pain-clbp-patients-an-international-multi-center-rct-100501620","NCT05811624","Lifestyle Intervention in Overweight\u002FObese Chronic Low Back Pain (CLBP) Patients: an International Multi-center RCT","Lifestyle Intervention in Overweight\u002FObese People Suffering From Chronic Low Back Pain: an International Multi-center Randomized Controlled Trial","BO2WL","Inclusion Criteria:\n\n* Adults (18 - 65 years)\n* Overweight (BMI ≥ 25 kg\u002Fm2) or obese (BMI ≥ 30 kg\u002Fm2) women and men.\n* CLBP (n=252), which is defined as nonspecific low back pain for at least 3 months duration, currently seeking care for low back pain and leg pain not ≥ 7 (on a maximum of 10) on a numeric rating scale.\n* Continue usual care 6 weeks prior to (to obtain a steady stat) and during study participation.\n* Depending on the country of inclusion: Native Dutch speaker (for Belgium) or Native German speaker (for Switzerland).\n\nExclusion Criteria:\n\n* Patients with BMI ≥ 40 kg\u002Fm² will be excluded as people being morbid obese are eligible to undergo abdominal surgery. Because BMI may not always correspond to the same body fat percentage in different individuals (e.g., athletic types with higher muscle mass may also have BMIs ≥ 25 km\u002Fkg²), each participant's body fat percentage will be measured using the TANITA and compared to the body fat percentage reference values. Participants with exceeding BMI but falling into the healthy fat percentage range (which is sex-, age- and ethnicity dependent will be excluded.\n* Pregnant, currently breastfeeding or given birth in preceding year.\n* Currently receiving dietary or exercise interventions or received in the past 6 weeks.\n* Show evidence of specific spinal pathology based on self-report (e.g., hernia, spi-nal stenosis, spondylolisthesis, infection, spinal fracture or malignancy), or a se-vere underlying comorbidity specific diagnoses that interfere with treatment (e.g., diagnosed diabetes, cardiovascular problems, metabolic diseases)\n* Other severe diseases based on current medication intake or being currently treated by a medical doctor for a specific diagnosis, (e.g. diagnosed eating disorders).\n* Ongoing problems or cases with insurance companies regarding their back.","65 Years",{"count":126,"type":21},252,[100],"Chronic low back pain (CLBP) is the most expensive cause of workrelated disability: it causes the highest number of years lived with disability. The most severe and debilitated CLBP patients often have comorbidities such as overweight and obesity. Despite the growing body of scientific literature pointing towards the close interaction between overweight\u002Fobesity and CLBP, few treatment programs for people with CLBP nowadays take overweight into account. Therefore this study will examine the added value of a behavioral weight reduction program (changes in diet, behavior and physical exercise) to current best evidence rehabilitation (pain neuroscience education plus cognition-targeted exercise therapy) for overweight or obese people with CLBP. An international, multicenter randomized controlled trial comparing a behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy versus pain neuroscience education and cognition-targeted exercise therapy alone, will be conducted. The primary outcome is pain and the primary endpoint was chosen at 12 months follow-up; secondary outcomes include health care use and daily functioning (see detailed description of outcomes for an overview of all secondary outcomes). If the promising results of the proof of concept study are corroborated, the new intervention will have a high socio-economic impact, including an annual health care cost reduction of €66 million in Switzerland, and €60 million in Flanders, and is expected to increase life expectancy in the long term.",[130,131],"Overweight or Obesity","Chronic Low-back Pain","2026-08-18",{"date":134,"type":31},"2026-08-20",{"date":136,"type":31},"2023-04-13",{"date":138,"type":21},"2028-11",{"name":140,"class":38},"Vrije Universiteit Brussel",2,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":124,"enrollmentInfo":149,"targetDuration":4,"studyType":98,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":141},"100425766","weight-reduction-in-clbp-100425766","NCT04824248","Weight Reduction in CLBP","The Added Value of a Behavioral Weight Reduction Program to Blended Rehabilitation in Patients With Chronic Low Back Pain: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Overweight (BMI ≥ 25 kg\u002Fm2) or obese (BMI ≥ 30 kg\u002Fm2) with chronic low back pain\n* Non-specific low back pain for at least 3 months' duration\n* Currently seeking care for low back pain\n* Native Dutch speaker\n* Access to internet and computer\u002Ftablet\u002Fsmartphone\n\nExclusion Criteria:\n\n* Leg pain of 7 or higher (on a maximum of 10) on a numeric rating scale\n* Evidence of specific spinal pathology (e.g., hernia, spinal stenosis, spondylolisthesis, infection, spinal fracture or malignancy)\n* Evidence of a severe underlying comorbidity (e.g. diabetes, cardiovascular problems, metabolic diseases)\n* BMI ≥ 40 kg\u002Fm2\n* Being pregnant or given birth in the preceding year\n* Currently receiving dietary or exercise interventions",{"count":150,"type":21},84,[100],"We will recruit overweight\u002F obese participants between the age of 18 and 65 with chronic nonspecific low back pain . The participants will be randomly assigned to one of two interventions (each lasting 10 weeks). All interventions will be delivered in a blended format and will be a combination of online education material and face-to-face sessions with a physical therapist. The first group (experimental intervention) will receive a behavioral weight reduction program combined with pain neuroscience education plus cognition-targeted exercise therapy. Participants in the second group (control intervention) will receive pain neuroscience education and cognition-targeted exercise therapy alone. Allocation to the groups will be at random. Participants and assessors will be blinded for group allocation. The primary outcomes is pain intensity. Secondary outcomes include other pain related outcomes, body composition, physical activity, sedentary behavior, dietary intake and function.",[131,130],[104,155,156,105,157,158],"chronic pain","physiotherapy","weight reduction","pain management",{"date":134,"type":31},{"date":161,"type":31},"2025-05-01",{"date":163,"type":21},"2027-12-01",{"name":140,"class":38},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":124,"enrollmentInfo":172,"targetDuration":4,"studyType":98,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":39},"100652387","palmitoylethanolamide-modulates-central-sensitisation-and-neuroinflammation-in-chronic-low-back-pain-100652387","NCT07772141","Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back Pain","Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back Pain: A Randomized Controlled Trial With Neurophysiological and Biomarker Correlates","Inclusion Criteria:\n\n* With chronic pain (more than 3 months)\n* Patients with NRS (4 -7)\n* MRI evidence of disc protrusion or prolapse limited to one or two lumbar discs, without extensive multi-level pathology\n* Diagnosed clinically with low back pain due to disc disease.\n* ASA I and ASA II\n\nExclusion Criteria:\n\n* Neurological disorders\n* psychiatric illness\n* pregnancy\n* prior spinal surgery\n* concurrent use of immunomodulatory drugs\n* contraindications to TMS.\n* Allergy to the drug",{"count":173,"type":21},106,[100],"Low back pain (LBP) is a public and occupational health problem that is a major professional, economic and social burden. Up to 84% of the general population will experience an episode of LBP during its life time, and recurrence rates are high. Acute LBP is the second reason for consultations in general medicine, and chronic LBP is the eighth. One in five LBP episodes result in sick leave. LBP represents 30% of sick leaves that are longer than 6 months, and 20% of work accidents. LBP has become the leading cause of exclusion from work before the age of 45, and the third cause of work disabilities in France.\n\nIn 2020 globally, LBP affected approximately 619 million people, making it the leading cause of disability worldwide. This number is projected to rise to 843 million by 2050, driven by population growth and aging.",[131],"2026-08-17",{"date":28,"type":31},{"date":180,"type":31},"2026-01-01",{"date":182,"type":21},"2027-06-10",{"name":184,"class":38},"Beni-Suef University",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":98,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":39},"100651409","multichannel-neuromuscular-electrical-stimulation-with-core-exercise-for-chronic-low-back-pain-100651409","NCT07760142","Multichannel Neuromuscular Electrical Stimulation With Core Exercise for Chronic Low Back Pain","Effects of Multichannel Neuromuscular Electrical Stimulation Combined With Core Exercise in Individuals With Chronic Non-Specific Low Back Pain: A Three-Arm Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 to 55 years.\n* Chronic non-specific low back pain lasting at least three months.\n* Low back pain not attributable to a specific trauma, infection, tumor, fracture, rheumatologic disease, or serious neurological disorder.\n* Pain intensity meeting the protocol threshold stated as VAS \\>=3. \\[TEYIT - because the outcome VAS is a 100-mm scale, clarify whether the intended eligibility threshold is \\>=30 mm (equivalent to 3\u002F10) rather than \\>=3 mm.\\]\n* Physical and cognitive ability to perform the core exercise program.\n* Willingness to attend two treatment sessions per week for six weeks (12 sessions total).\n* Voluntary participation and provision of written informed consent.\n\nExclusion Criteria:\n\n* Age younger than 18 years or older than 55 years.\n* Low back pain due to disc herniation, spinal stenosis, fracture, tumor, infection, or inflammatory disease.\n* Nerve root involvement, marked sensory loss, or muscle weakness.\n* Previous lumbar spine surgery.\n* Pacemaker or other electronic implant; pregnancy; epilepsy; or active cancer.\n* Open wound or skin disease in the treatment area.\n* Physical therapy for low back pain within the previous month or continuation of another low back pain treatment during the study period.","55 Years",{"count":194,"type":21},45,[100],"Chronic non-specific low back pain is a common musculoskeletal condition that can adversely affect daily activities, functional capacity, sleep, and quality of life. Exercise therapy is a key component of conservative management, and core exercises are used to improve trunk control and the coordinated function of the abdominal, lumbar, and pelvic musculature. Neuromuscular electrical stimulation may be added to exercise to facilitate muscle activation and support pain management; however, the additional clinical benefit of different multichannel stimulation programs remains uncertain.\n\nThis three-arm randomized controlled trial evaluates the effects of two multichannel neuromuscular electrical stimulation programs added to a standardized core exercise program in adults with chronic non-specific low back pain. Forty-five participants are allocated in a 1:1:1 ratio to (1) core exercise plus a lumbar strengthening stimulation program, (2) core exercise plus a muscle relaxation stimulation program, or (3) core exercise alone. Treatment is delivered twice weekly for six weeks (12 sessions). In the two stimulation groups, StimaWELL 120MTRS therapy is applied for 30 minutes at 40 °C. Outcomes are assessed at baseline and at week 6. The primary outcome is low back pain intensity measured with a 100-mm Visual Analog Scale. Secondary outcomes are disability, patient-specific functional status, quality of life, and insomnia severity.",[131],[199],"neuromuscular electrical stimulation",{"date":132,"type":31},{"date":202,"type":31},"2026-08-14",{"date":204,"type":21},"2026-12-30",{"name":206,"class":38},"Uskudar University",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":18,"enrollmentInfo":213,"targetDuration":4,"studyType":98,"phases":215,"briefSummary":217,"conditions":218,"keywords":226,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":39},"100651966","early-phase-1-evaluation-of-an-online-peri-operative-health-education-platform-for-patients-undergoing-spine-surgery-ready-set-recover-100651966","NCT07766824","Evaluation of an Online Peri-operative Health Education Platform for Patients Undergoing Spine Surgery: Ready Set Recover","Inclusion Criteria:\n\n* Patients deemed candidates for medium-\u002Flong-segment spinal fusion\n* Patients who score a \\> 4 on a 0-10 NRS for the question \"How motivated are you to participate in this research study?\"\n* At least 18 years of age and not older than 80 at the time of study enrollment •Ability to read and understand English\n* Daily access to the internet via cell phone, tablet, or computer\n\nExclusion Criteria:\n\n* Have received epidural steroid injection for low back pain, lumbosacral radiculopathy, or scoliosis in the prior 3 months\n* Have received a surgical intervention for low back pain, lumbosacral radiculopathy, or scoliosis in the previous 6 months\n* Concurrent diagnosis of cancer\n* Cognitive impairment\n* Severe comorbidities (e.g., terminal illness, severe organ failure)\n* Non-elective\u002Femergency surgery in the past",{"count":214,"type":21},60,[216],"EARLY_PHASE1","Chronic back pain is the world's leading cause of disability, with spine surgery being a common yet costly intervention. However, many patients experience suboptimal recovery, with persistent pain and functional limitations contributing to high healthcare utilization and costs. Traditional surgical pathways often overlook the role of mental well-being and patient engagement in recovery. However, research indicates that interventions promoting self-management and stress reduction can lead to improvements in pain, faster recovery, and reduced hospital readmissions.\n\nEvidence shows that preoperative psychosocial factors, such as anxiety and depression, significantly predict post-surgical outcomes, yet structured perioperative support is lacking. To address this gap, Ready Set Recover (RSR), a mobile health (mHealth) intervention, provides education, behavioral strategies, and psychosocial support to enhance surgical preparedness and optimize post-surgical recovery. By addressing both psychological and behavioral factors, RSR has the potential to fill a critical gap in perioperative care. As a scalable digital platform, RSR offers an accessible, cost-effective solution that can be easily integrated into existing surgical care models, reducing the burden on healthcare providers while empowering patients to take an active role in their healing process.\n\nRSR aims to accomplish this by integrating evidence-based components such as cognitive behavioral therapy, mindfulness, gratitude practices, and guided movement to foster patient empowerment and sustainable health practices in the pre- and post-surgical periods. The platform provides patients with a structured and flexible tool to improve self-efficacy, adherence to post-surgical recommendations, and the overall surgical recovery experience.\n\nThis study aims to evaluate the feasibility and acceptability of RSR through an explanatory mixed-methods pilot randomized controlled trial (RCT) in patients undergoing medium-to-long segment spinal fusion at Oregon Health \\& Science University.\n\nAim 1 assesses feasibility and acceptability by measuring patient engagement, intervention completion rates, and satisfaction.\n\nAim 2 qualitatively evaluate barriers and facilitators to implementation of RSR within the clinic setting via provider, patient, and clinic stakeholder semi-structured interviews.\n\nAim 3 establishes a patient community advisory board (CAB) to guide future research and the development of a Phase II Small Business Technology Transfer (STTR) efficacy trial.\n\nFindings from this study will inform the refinement and scalability of RSR as a low-burden, cost-effective solution to improve surgical outcomes. Insights gained from this research may extend beyond spine surgery, informing the development of digital health interventions for other surgical populations, ultimately advancing patient-centered, technology-driven approaches to perioperative care.",[219,220,25,221,75,222,223,224,225],"Medium-\u002FLong-segment Spinal Fusion Patients","Spine Surgeons","Scoliosis Patients","Lumbar Spondylolisthesis","Cervical Spondylosis and Spondylolisthesis","Post Laminectomy Cervical Syndrome","Cervical Myelopathy",[227,228,229,230,231,232,233,234],"back surgery","medium-\u002Flong-segment spinal fusion","mindfulness","Perioperative Care","Whole Person Care","Chronic low back pain","Feasibility","Qualitative","NOT_YET_RECRUITING","2026-08-10",{"date":177,"type":31},{"date":239,"type":21},"2026-09-30",{"date":241,"type":21},"2027-09-30",{"name":243,"class":38},"National University of Natural Medicine",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":98,"phases":253,"briefSummary":254,"conditions":255,"keywords":260,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":271},"100607611","managing-pain-using-optimized-sequences-by-adjusting-parameters-with-independent-current-control-100607611","NCT07190807","Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control","Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control (MOSAIC Study)","MOSAIC","Key Inclusion Criteria:\n\n* Persistent spinal pain syndrome (PSPS) Type I (or non-surgical refractory back pain), or PSPS Type II (Failed Back Surgery Syndrome, FBSS) diagnosis.\n* Diagnosed with chronic pain of the trunk and\u002For limbs for at least 6 months.\n* 18 years of age or older when written informed consent is obtained\n* Able to independently read and complete all questionnaires and assessments provided in English.\n* Signed a valid, IRB or EC approved informed consent form (ICF) provided in English.\n\nKey Exclusion Criteria:\n\n* Any pain-related diagnosis, medical or psychological condition that, in the Investigator's judgment might confound reporting of study outcomes (e.g., vascular or neurogenic claudication, osteoarthritis, plantar fasciitis, pelvic pain, anginal pain, chronic migraine, acute herniated disc, malignancy, untreated major depression, injury claim).\n* Significant cognitive impairment at Screening and Baseline visit that, in the opinion of the Investigator, would reasonably be expected to impair the study candidate's ability to participate in the study\n* A female who is pregnant, lactating, or is of childbearing potential and planning to get pregnant during the study or not using adequate contraception.\n* Participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study.",{"count":20,"type":21},[100],"Study to evaluate the effectiveness of time variant pulse (TVP)-SCS in patients with chronic pain using commercially approved Boston Scientific SCS Systems per local Instructions for use (IFU).\n\nIn addition, to compile real-world clinical outcomes in subjects with chronic, intractable low back and\u002For leg pain.",[68,256,257,131,258,259],"Intractable Pain","Low Back Pain","Chronic Leg Pain","Leg Pain",[261],"Spinal Cord Stimulation",{"date":263,"type":31},"2026-08-11",{"date":265,"type":31},"2025-11-07",{"date":267,"type":21},"2029-05",{"name":269,"class":270},"Boston Scientific Corporation","INDUSTRY",7,{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":279,"targetDuration":281,"studyType":22,"phases":4,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":294},"100579666","intracept-minimally-invasive-procedure-for-vertebrogenic-back-pain-100579666","NCT06827262","Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain","IMPROVE","Inclusion Criteria:\n\n* Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).\n* Signed a valid, IRB\u002FEC-approved informed consent form.\n\nExclusion Criteria:\n\n* Meets any contraindications per locally applicable Instructions for Use (IFU).",{"count":280,"type":21},1500,"60 Months","Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.",[131,284],"Vertebrogenic Pain Syndrome",[286,287,257],"Intraosseous basivertebral nerve ablation","Axial low back pain",{"date":263,"type":31},{"date":290,"type":31},"2025-03-26",{"date":292,"type":21},"2034-07",{"name":269,"class":270},19,{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":124,"enrollmentInfo":302,"targetDuration":4,"studyType":98,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":39},"100628417","efficacy-of-low-dose-laser-acupuncture-for-low-back-pain-100628417","NCT07461363","Efficacy of Low-Dose Laser Acupuncture for Low Back Pain","Effect of Low-Dose Laser Acupuncture on Low Back Pain: A Randomised Control Trial","Inclusion Criteria:\n\n* Low back pain for ≥12 weeks\n* Pain intensity VAS ≥3 cm at Visit 1 (baseline)\n* Age 18-65 years\n* Able and willing to provide written informed consent\n* Able and willing to attend treatment sessions at Pusat Sejahtera, Universiti Sains Malaysia and complete the 3-month follow-up phone assessment\n\nExclusion Criteria:\n\n* Pregnant or planning pregnancy; females unwilling to use pregnancy prevention during the study\n* Current or past history of trauma or cancer\n* Prior spine surgery\n* Severe infection (e.g., tuberculosis, pyogenic abscess)\n* Fever ≥38°C lasting ≥48 hours at recruitment\n* Cauda equina syndrome\n* Significant spinal cord compression with serious disability (per medical history)\n* Osteoporosis requiring pharmacologic treatment\n* Severe dementia, cognitive impairment, other major cerebral disease, or severe psychiatric\u002Fpsychological disorder\n* Significant renal or hepatic disease\n* BMI ≥34.9 kg\u002Fm²\n* History of recreational drug abuse\n* Use of systemic steroids within the past 6 months\n* Use of any analgesics (including paracetamol) within the past 30 days\n* Acupuncture treatment within the past 30 days",{"count":65,"type":21},[100],"This study will evaluate whether low-dose laser acupuncture can reduce pain and improve daily function in adults with chronic low back pain. The trial is a double-blinded, randomized, two-arm, parallel, multi-centred study.",[25],"2026-08-08",{"date":263,"type":31},{"date":309,"type":21},"2026-09-01",{"date":311,"type":21},"2028-08-15",{"name":313,"class":38},"Mun Fei Yam",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":39},"100647628","ultrasound-guided-proximal-superior-cluneal-nerve-block-for-superior-cluneal-nerve-entrapment-100647628","NCT07712406","Ultrasound-Guided Proximal Superior Cluneal Nerve Block for Superior Cluneal Nerve Entrapment","Clinical Outcomes of Ultrasound-Guided Proximal Superior Cluneal Nerve Block in Patients With Superior Cluneal Nerve Entrapment","PRO-SCN","Inclusion Criteria:\n\n* Age 18-75 years.\n* Chronic low back and\u002For gluteal pain persisting for at least 3 months.\n* Localized pain and\u002For tenderness over the posterior iliac crest.\n* At least 50% reduction in pain intensity following diagnostic superior cluneal nerve block.\n* Failure of conservative treatment.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Previous superior cluneal nerve surgery.\n* Active local or systemic infection.\n* Bleeding disorders or contraindications to the procedure.\n* Allergy to study medications.\n* Pregnancy.\n* Severe cognitive impairment or inability to complete study assessments.\n* Additional interventional pain procedures involving the affected region during follow-up.","75 Years",{"count":324,"type":21},40,"Superior cluneal nerve entrapment (SCNE) is an underrecognized cause of chronic low back pain and gluteal pain that may mimic lumbar spine disorders. Ultrasound-guided proximal superior cluneal nerve block has increasingly been used in routine clinical practice .Diagnostic superior cluneal nerve block is commonly used to confirm the diagnosis, whereas ultrasound-guided proximal superior cluneal nerve block has emerged as a therapeutic option.\n\nThis prospective observational cohort study aims to evaluate the clinical outcomes of ultrasound-guided proximal superior cluneal nerve block in patients with clinically diagnosed superior cluneal nerve entrapment who undergo the procedure as part of routine clinical care. Pain intensity, disability, and neuropathic pain characteristics will be assessed at baseline and during follow-up to evaluate treatment outcomes.",[327,25],"Superior Cluneal Nerve Entrapment",[327,329,25],"Ultrasound-Guided Nerve Block","2026-07-25",{"date":332,"type":31},"2026-07-28",{"date":334,"type":31},"2026-05-15",{"date":336,"type":21},"2026-12",{"name":338,"class":339},"Gaziosmanpasa Research and Education Hospital","OTHER_GOV",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":16,"minAge":347,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":98,"phases":350,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":368},"100478314","lumbar-operatively-inserted-perqdisc-artificial-implant-following-nulcectomy-lopain2-100478314","NCT05508360","\"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy\" (LOPAIN2)","LOPAIN2","Inclusion Criteria:\n\n* Patient is skeletally mature aged 22-70.\n* Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 but the discogenic pain must be limited to a single level.\n* Patient has adequate disc height (6mm) at the level to be treated\n* Patient has exhausted a minimum of 6 months of conservative treatment for their back (e.g. physical therapy, medications, injections, life style changes, etc).\n* Patient has a preoperative Oswestry Disability questionnaire score ≥ 40 out of 100 points (40\u002F100)\n* Patient has a low back pain Visual Analog Scale (VAS) ≥ 40 mm (4 cm)\n* Patient has signed the approved Informed Consent Form.\n* All surgeries must be approved by the Medical Advisory Board (MAB)\n\nExclusion Criteria:\n\n* Patient has less than 6 mm of disc height.\n* Patient has had prior lumbar spine surgery (nucleoplasty at non-index level is considered acceptable).\n* Patient has had spinal fusion in the lumbar or thoracic intervertebral spaces. Cervical fusion is allowed as long as there are no neurologic deficits in the lower extremities.\n* Patient has spondyloarthropathy or other spondylolisthesis greater than 2 mm.\n* Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis.\n* Patient has significant facet disease. Significant is defined as pain improvement of 80% or more following image-guided medial branch blocks of the target level according to SIS guidelines (diagnostic, contrast controlled).\n* Patient has any known active malignancy.\n* Patient has previously undergone or currently on immunosuppressive therapy. Steroids used to treat inflammation are allowed.\n* Patient has active or local systemic infection.\n* Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other autoimmune disease including AIDS, ARC and HIV.\n* Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management.\n* Patient has osteopenia of the spine (T-score of -1.0 or lower). A DEXA scan should be performed to rule out patients considered at risk for osteopenia.\n* Patient has morbid obesity defined as a body mass index (BMI) more than 40 or a weight of more than 45 kg (100 lbs.) over ideal body weight.\n* Patient has a known allergy to silicone or barium sulfate.\n* Patient has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.\n* Patient has a significant Schmorl's node in the level to be treated. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes).\n* Patient has motion of less than 3 degrees on pre-operative lateral flexion\u002Fextension radiographs.\n* Patient belongs to a vulnerable population or has a condition such that his\u002Fher ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally, disabled, prisoner, chronic alcohol\u002F substance abuser)\n\nIntraoperative Exclusion Criteria:\n\n* Protrusion of the 20A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps.\n* Patient has a violated endplate as determined by imaging balloons during fluoroscopy.\n* Patient has a disc space that is too narrow for implantation. MIPL Specific\n* Poor radiological visualization of Kambin's triangle.\n* Sustained irritation of the exiting nerve root during any aspect of the annular dilation technique (leg movement or if performing with electrical monitoring) in spite or repositioning instruments.","22 Years",{"count":349,"type":21},72,[100],"This study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.",[353,131],"Degenerative Disc Disease",[353,355,25,356,357,358,257],"DDD","cLBP","Disc Herniation","Nucleus Replacement","2026-07-24",{"date":361,"type":31},"2026-07-27",{"date":363,"type":31},"2022-08-22",{"date":365,"type":21},"2030-08-22",{"name":367,"class":270},"Spinal Stabilization Technologies",11,{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":16,"minAge":377,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":98,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":39},"100649192","algorithm-informed-decision-making-to-advance-pain-treatment-100649192","NCT07731750","Algorithm-informed Decision-making to Advance Pain Treatment","Algorithm-informed Decision-making to Advance Pain Treatment (ADAPT Study)","ADAPT","Inclusion Criteria:\n\n* Participants must meet the definition of Chronic Low Back Pain (cLBP) described in the NIH Task Force Report on Research Standards for cLBP, i.e., low back pain present at least six months, and present more than half of those days.2\n* Individuals must have a pain interference score of ≥60 on PROMIS Pain Interference. The normal population mean for pain interference is 50. Participants must be 1 standard deviation (SD) above the population mean (\\>=60) for inclusion.\n* Individuals must be willing and eligible to receive at least three of the four proposed interventions.\n* Able to stand for at least 10 minutes\n\nExclusion Criteria:\n\n* Red flags suggesting the presence of an identifiable cause of low back pain, including fever, weight loss, initiation of pain following major trauma, immunosuppression, IV drug use, recent bacterial infection, severe or persistent sensory or motor involvement of bowel, bladder, or lower extremity.\n* Unable to read, write of speak fluent English\n* Visual or hearing difficulties that would preclude participation\n* Active uncontrolled drug\u002Falcohol addiction\n* Individuals receiving new disability or compensation or involved in litigation in the past 12 months.\n* Pregnancy or breastfeeding\n* Individuals on high doses of opioids (over 100 Oral Morphine Equivalents \\[OME\\] per day).\n* Upcoming scheduled back surgery, back surgery within the last year, or more than one back surgery in the past.\n* History of discitis osteomyelitis (spine infection) or spine tumor\n* History of an autoimmune disorder such as ankylosing spondylitis, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, or lupus\n* History of cauda equina syndrome or spinal radiculopathy\n* Diagnosis of schizophrenia or schizoaffective diagnosis\n* Diagnosis of any vertebral fracture in the last 6 months\n* Osteoporosis requiring treatment (vitamin D and calcium supplements are acceptable)\n* Cancer\n\n  * History of any bone-related cancer or cancer that metastasized to the bone\n  * Currently in treatment for cancer or plan to start cancer treatment in the next 12 months\n  * History of any cancer treatment in the last 24 months\n* Life expectancy is less than 2 years\n* Current\u002Fplanned (in the next 2 years) enrollment in another study of a device or investigational drug that would interfere with this study, this may include participation in a blinded trial.\n* Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators. This would include but not be limited to severe psychiatric disorders, active suicidal ideations or recent suicide attempts","25 Years",{"count":379,"type":21},500,[100],"Researchers are exploring how certain personal factors, such as symptoms, health history, and lifestyle, may help predict which treatments will work best for someone.\n\nThe purpose of this study is to evaluate how well a study algorithm chooses the best treatments for a patient when considering their unique pain characteristics.",[131],"2026-07-22",{"date":332,"type":31},{"date":386,"type":21},"2026-07",{"date":388,"type":21},"2030-07",{"name":390,"class":38},"University of Michigan",{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":16,"minAge":398,"maxAge":18,"enrollmentInfo":399,"targetDuration":4,"studyType":98,"phases":400,"briefSummary":402,"conditions":403,"keywords":405,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":39},"100543403","phase-1-psilocybin-in-chronic-low-back-pain-and-depression-100543403","NCT06355414","Psilocybin in Chronic Low Back Pain and Depression","Psilocybin and Affective Function in Chronic Lower Back Pain Depression","Inclusion Criteria:\n\n* 21 to 80 years old\n* Have given written informed consent\n* Report low back pain as ongoing problem ≥ 3 months and any low back pain on at least half of the days over the past 6 months (consistent with NIH Consensus Recommendations for defining CLBP; other chronic pain problems can be present, but CLBP must be reported as primary)\n* Report at least moderate depression symptoms Grid-Hamilton Depression Rating Scale (GRID-HAMD) ≥ 17\n* Fluent in English\n* At least high school level of education\n* Agree to abstain from any psychoactive drugs on the day prior to and the day of the drug administration session\n* Women who are of childbearing potential and sexually active who are not practicing an effective means of birth control must agree to practice an effective means of birth control throughout the duration of the study\n* Be judged by study team clinicians to be at low risk for suicidality\n* Concurrent psychotherapy or pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs), serotonin and norephinephrine reuptake inhibitors (SNRIs), and\u002For bupropion (\\\u003C 300 mg bupropion) is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening and is expected to remain stable during participation in the study.\n* Concurrent psychotherapy is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening and is expected to remain stable during participation in the study\n* Be otherwise medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests; CBC, comprehensive metabolic panel (CMP), urine beta-human chorionic gonadotropin (HCG), urine toxicology screen.\n* Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he\u002Fshe consumes on a usual morning, before arriving at the research unit on the mornings of drug session days. If the participant does not routinely consume caffeinated beverages, he\u002Fshe must agree not to do so on session days.\n* Agree not to take any as needed (PRN) medications on the mornings of drug sessions\n* Agree not to take sildenafil (Viagra®), tadalafil, or similar medications within 72 hours of each drug administration\n* Agree that for one week before each drug session, he\u002Fshe will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.\n* Have limited lifetime use of hallucinogens (the following criteria are preferred: no use in the past 5 years; total hallucinogen use less than 10 times)\n\nExclusion Criteria:\n\n* Lifetime history of serious psychiatric (other than depression) or neurological disorders, including bipolar disorder, psychosis, or seizure disorder\n* History (past 2 years) of severe substance use disorder or current (past six months) substance use disorder of moderate severity\n* Clinically significant suicidal ideation (e.g. with strong intent or means) within past 6 months or history (past 5 years) of suicide attempt\n* Medical condition incompatible with psilocybin administration (e.g., cardiovascular)\n* On unstable\u002Fchanging dose of opioid, benzodiazepine or other psychoactive or pain medication within 4 weeks prior to enrollment and\u002For unable to abstain from medication on drug administration day\n* Current use\u002Fpositive toxicology for illicit drugs or positive breath alcohol test at screening and prior to each drug administration session.\n* Clinically significant transaminitis- aspertate aminotransferase (AST) or alanine aminotransferase (ALT) greater than two times normal value).\n* Women who are pregnant (as indicated by a positive urine pregnancy test assessed at intake and before each drug session) or nursing;\n* Women who are of childbearing potential and sexually active who are not practicing an effective means of birth control.\n* Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant ECG abnormality (e.g., atrial fibrillation), prolonged corrected QT interval (QTc) interval (i.e., QTc \\> 450 msec), heart valve, or transient ischemic attack (TIA) in the past year.\n* History of seizures and\u002For epilepsy with history of seizures.\n* Type 1 diabetes.\n* BMI \\\u003C 18\n* Medical conditions contraindicated for methylphenidate administration:\n\n  1. Concomitant use of Monoamine oxidase inhibitors (MAOIs), or use within 14 days of MAOI discontinuation\n  2. Family history or diagnosis of Tourette's syndrome\n  3. Known Fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltose insufficiency\n  4. Glaucoma\n  5. Known hypersensitivity to methylphenidate\n  6. Marked agitation, anxiety, and tension\n  7. Motor tics\n* Currently taking on a regular (e.g., daily) basis any antidepressant medications other than SSRIs, SNRIs, or bupropion, or any other medications that have a primary centrally-acting serotonergic effect, including MAOIs. Bupropion dosage must be \\\u003C 300 mg in order to be included. For individuals who have intermittent or PRN use of such medications and\u002For who taper off such medications after regular use, psilocybin sessions will not be conducted until at least 14 days or 5 half-lives (whichever is greater) of the agent have elapsed after the last dose.\n* Nicotine dependence that would be incompatible with an individual to be nicotine free for 8-10 hours on a psilocybin session day\n* Have a first degree relative with schizophrenia or other psychotic disorders (except substance\u002Fmedication-induced or due to another medical condition), or bipolar I disorder","21 Years",{"count":324,"type":21},[401],"PHASE1","This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D).\n\nParticipants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose). Participants will be asked to complete assessments of pain, depressive symptoms, and more general questionnaires regarding the participants experiences during the experimental sessions and the associated enduring effects.",[131,404],"Depression",[406,131,404],"Psilocybin",{"date":359,"type":31},{"date":409,"type":31},"2024-04-22",{"date":204,"type":21},{"name":114,"class":38},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":98,"phases":422,"briefSummary":423,"conditions":424,"keywords":425,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":141},"100552348","improving-health-for-patients-with-chronic-low-back-pain-in-rural-communities-through-telerehabilitation-100552348","NCT06471920","Improving Health for Patients With Chronic Low Back Pain in Rural Communities Through Telerehabilitation","ARBOR Telehealth: Improving Health for Patients With Chronic Low Back Pain in Rural Communities Through Improved Access to Telerehabilitation","ARBOR-Th","Inclusion Criteria:\n\n* Primary care visit in the past 90 days with an LBP-related International Classification of Diseases (ICD-10) diagnosis.\n* Age 18 years or older.\n* At least moderate levels of pain and disability requiring Oswestry score ≥24% and average pain rating ≥ 4\u002F10 points.\n* Meets NIH Task Force definition of chronic LBP based on two questions: 1) How long has LBP has been an ongoing problem? and 2) How often has LBP been an ongoing problem over the past 6 months? A response of greater than 3 months to question 1, and \"at least half the days in the past 6 months\" to question 2 is required to satisfy the NIH definition of chronic LBP.\n* Can speak and understand English.\n* Access to video-enabled device and Internet.\n\nExclusion Criteria:\n\n* Recent history (last 6 months) of lumbar spine surgery.\n* Possible non-musculoskeletal cause for low back pain symptoms (e.g., pregnancy).\n* Evidence of serious pathology as a cause of LBP including neoplasm, inflammatory disease (e.g., ankylosing spondylitis), vertebral osteomyelitis, etc.\n* Neurological disorder resulting in severe movement disorder, or schizophrenia or other psychotic disorder.\n* Knowingly pregnant.",{"count":421,"type":21},434,[100],"Physical therapy is the first line of treatment for patients with low back pain (LBP) and has been shown to be a cost-effective method for improving pain and disability in patients with chronic LBP; however, despite this effectiveness, only 7-13% of patients go on to receive physical therapy services with patients in rural communities being especially limited to do lack of provider availability, transportation, and missed work time leading to greater rates of LBP-related disability and opioid consumption. With the rapid emergence of digital treatment approaches to physical therapy (i.e., telerehabilitation), access could be improved by reducing or eliminating many barriers that patients report; however, it is unclear how to appropriately incorporate digital treatment approaches into existing health care models. The investigators propose a prospective randomized clinical trial conducted at a health system serving rural communities to determine the effectiveness of innovative risk-informed telerehabilitation versus standard educational control for patients with chronic LBP that will match individual patients with specific physical therapy delivery (physical therapy telehealth visits or psychologically informed physical therapy telehealth visits) based on the patient's psychosocial risk of poor outcomes.",[131],[104,105,426,107,427,428],"Telehealth","rural","opioid","2026-07-20",{"date":383,"type":31},{"date":432,"type":31},"2025-01-27",{"date":434,"type":21},"2028-08-31",{"name":114,"class":38},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":16,"minAge":347,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":98,"phases":446,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":141},"100605134","phase-3-veterans-intervention-blending-neuromodulation-and-yoga-for-chronic-low-backpain-treatment-vibrant-100605134","NCT07158567","Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low BackPaiN Treatment: VIBRANT","Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low Back PaiN Treatment: VIBRANT","VIBRANT","Inclusion Criteria:\n\n* 1 month stability in pain management strategies.\n* Can read and speak English.\n* Able to participate in strengthening, stretching, range of motion exercise via yoga as determined by study physician.\n* Chronic Low Back Pain (CLBP): pain in the low back that persists for \\>6 months and is of moderate to severe intensity with a score of \\>5 on specific items on the BPI demonstrating disability of at least 20% on the Oswestry Disability Index (ODI).\n\nExclusion Criteria:\n\n* Contraindications to iTBS\u002FTMS (e.g. epilepsy, psychotic spectrum disorders \\[i.e. bipolar, schizophrenia\\], history of anoxic brain injury).\n* Moderate to severe heart disease.\n* Contraindications to MRI (e.g., claustrophobia, implanted ferromagnetic device such as pacemaker or cardiac defibrillator).\n* Pain believed to be associated with cardiac or ischemic conditions.\n* Epilepsy, active seizure disorder, personal history of a seizure or individuals with a family history of epilepsy or seizure in a first degree relative.\n* Current prescription of psychostimulants (e.g., amphetamines), anticholinergics, tricyclic antidepressants, and antipsychotics or other medications that may increase their risk of having seizures.\n* Intracranial lesion.\n* History of ischemic or hemorrhagic stroke.\n* History of moderate to severe TBI.\n* History of or current psychosis not due to an external cause (e.g., due to illicit drug use).\n* Other neurological conditions (e.g., neurodegenerative disorders).\n* Active suicidal ideation with Columbia Suicide Severity Rating Scale(CSSRS) 3 .\n* Are pregnant or nursing.\n* Within 12 weeks of a major surgery\u002Foperation.",{"count":445,"type":21},213,[447],"PHASE3","The objectives of this VA Merit application are to demonstrate efficacy of combined intermittent theta burst (iTBS) and yoga (iTBS+yoga) intervention on improving pain, function, analgesic use, self-efficacy, quality of life and well-being among Veterans with chronic low back pain (CLBP). This Merit project will directly benefit Veterans and VA Services by demonstrating efficacy of a new, non-medication treatment for Veterans with CLBP in need of non-opioid treatment options. Neuromodulation including iTBS is now offered at over 50 VA hospitals and yoga is among the complementary and integrative health programs being rolled out as a part of VAs Whole Health implementation efforts. Thus, should iTBS+yoga ultimately prove to be efficacious, VA facilities will be well-poised to offer this treatment. A novel, activity-based, non-medication treatment for Veterans with CLBP is of great need given the high prevalence of CLBP.",[25,450],"Musculoskeletal Pain",[104,452,453,454,455,456,457],"transcranial magnetic stimulation","TMS","neuromodulation","yoga","complementary and integrative health","musculoskeletal pain","2026-07-17",{"date":460,"type":31},"2026-07-21",{"date":462,"type":21},"2026-08-01",{"date":464,"type":21},"2031-12-31",{"name":466,"class":467},"VA Office of Research and Development","FED",{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":98,"phases":477,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":487,"leadSponsor":488,"locationsCount":39},"100597076","durability-of-yoga-for-veterans-with-low-back-pain-100597076","NCT07053787","Durability of Yoga for Veterans With Low Back Pain","Durability of Yoga for Treating Veterans With Chronic Low Back Pain","Inclusion Criteria:\n\n* VA patients\n* Diagnosis of chronic low back pain \\> 3 months\n* Pain rated 4\u002F10 or higher\n* No new pain treatments in the past month\n* Willing to attend intervention\n* Complete 5 assessments\n* Respond to text assessments\n* Practiced yoga \\\u003C 3x in the last 6 months\n* Unless medically necessary, agree to not change pain treatment during intervention\n\nExclusion Criteria:\n\n* Back surgery within the last 1 year\n* Pain due to specific systemic (e.g., scleroderma, fibromyalgia) or non-musculoskeletal problem (neuropathy)\n* Positive Romberg test (with or without sensory neuropathy)\n* Severe vertebral disk problems, sciatica or nerve compression \\>3 months\n* Serious or unstable psychiatric illness (e.g., unmanaged psychosis, manic episode, or substance dependence)\n* Serious coexisting medical illness (e.g., cancer, COPD, BMI\\> 40)",{"count":476,"type":21},176,[100],"Chronic low back pain is a prevalent condition among VA patients, but many current treatment options have side effects or limited effectiveness. Veterans with chronic low back pain (cLBP) experience increased disability, functional challenges, and reduced quality of life. A prior VA funded study of Yoga for VA patients with cLBP found that yoga can reduce pain and disability at 3 and 6 months after enrollment. However, the long-term effects and maintenance of yoga practice is unknown. The current study will test an intervention designed to promote long-term yoga practice and long-term health outcome benefits at 12 and 18 months after enrollment.",[25],[104,455,481,482],"disability","durability","2026-07-14",{"date":485,"type":31},"2026-07-16",{"date":309,"type":21},{"date":464,"type":21},{"name":466,"class":467},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":500,"conditions":501,"keywords":505,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":39},"100646096","spine-risk-ve-multimodal-predictive-model-for-failed-back-surgery-syndrome-in-venezuelan-surgical-patients-100646096","NCT07693517","SPINE-RISK VE: Multimodal Predictive Model for Failed Back Surgery Syndrome in Venezuelan Surgical Patients","SPINE-RISK VE: Development and Internal Validation of a Multimodal Preoperative Predictive Model for Failed Back Surgery Syndrome Using Inflammatory Biomarkers, Lumbar MRI Findings, and Psychosocial Factors in Venezuelan Surgical Patients","SPINE-RISK VE","Inclusion Criteria:- Age 18 years or older\n\n* Confirmed indication for elective lumbar spine surgery (discectomy, spinal fusion, or decompression) for degenerative lumbar disease\n* Availability of preoperative lumbar MRI (with and without gadolinium contrast) within 6 months before surgery\n* Availability of standard preoperative laboratory panel (CRP, CBC with differential, albumin, HbA1c, ESR) within 30 days before surgery\n* Ability to complete validated psychosocial instruments (PHQ-9, PCS) in Spanish\n* Provision of written informed consent prior to any study procedure\n* Attending one of the three participating Venezuelan referral centers during the recruitment period\n\nExclusion Criteria:- Emergency lumbar spine surgery\n\n* Active spinal infection or spinal tumor requiring oncological surgery\n* Traumatic spinal fracture as primary indication\n* Cognitive impairment preventing completion of self-report psychosocial instruments\n* Active psychiatric emergency at time of preoperative assessment\n* Prior participation in another clinical trial that could influence surgical or pain outcomes\n* Inability to complete 12-month postoperative follow-up (geographic inaccessibility, planned relocation, or terminal illness)\n* Age under 18 years","100 Years",{"count":499,"type":21},150,"SPINE-RISK VE is a prospective multicenter cohort study designed to develop and internally validate a multimodal preoperative predictive model for Failed Back Surgery Syndrome (FBSS), now classified as Persistent Spinal Pain Syndrome Type 2 (PSPS-T2) per ICD-11 (code MG30.51), in Venezuelan adults patients undergoing elective lumbar spine surgery.\n\nThe model integrates three variable domains obtainable from routine preoperative evaluation at zero additional cost to the patient: (1) inflammatory laboratory biomarkers (C-reactive protein \\[CRP\\], neutrophil-to-lymphocyte ratio \\[NLR\\], albumin, glycated hemoglobin \\[HbA1c\\], erythrocyte sedimentation rate \\[ESR\\]); (2) preoperative lumbar magnetic resonance imaging (MRI) findings (Modic changes, Pfirrmann disc degeneration grade, foraminal stenosis, number of surgical levels, spondylolisthesis); and (3) validated psychosocial instruments (Patient Health Questionnaire-9 \\[PHQ-9\\], Pain Catastrophizing Scale \\[PCS\\], smoking status, benzodiazepine use, prior lumbar surgery).\n\nAnalysis proceeds in two phases: Phase 1 applies multivariable logistic regression with Least Absolute Shrinkage and Selection Operator (LASSO) variable selection to generate a printable clinical nomogram; Phase 2 applies a random forest machine learning algorithm with 10-fold cross-validation. Model reporting follows Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis plus Artificial Intelligence (TRIPOD+AI) guidelines.\n\nSPINE-RISK VE aims to produce the first validated multimodal predictive model for PSPS-T2\u002FFBSS was developed in a Latin American surgical cohort, providing neurosurgeons with an evidence-based preoperative risk stratification tool applicable without Additional technological infrastructure.",[502,25,503,504],"Persistent Spinal Pain Syndrome Type 2 (PSPS-T) Lower Spine","Postoperative Pain","Lumbar Spine Surgery",[506,507,508,509,510,511,512,513,514,515],"predictive model","machine learning","random forest","LASSO regression","Modic changes","inflammatory biomarkers","pain catastrophizing","TRIPOD+AI","Venezuela","Latin America","2026-07-08",{"date":518,"type":31},"2026-07-10",{"date":520,"type":21},"2026-09-04",{"date":522,"type":21},"2028-02-10",{"name":524,"class":38},"juan jose valero quintero,MD",{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":124,"enrollmentInfo":532,"targetDuration":4,"studyType":98,"phases":534,"briefSummary":535,"conditions":536,"keywords":540,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":39},"100646665","high-intensity-laser-therapy-versus-transforaminal-epidural-steroid-injection-in-chronic-lumbar-disc-herniation-related-low-back-and-radicular-pain-100646665","NCT07688915","High-Intensity Laser Therapy Versus Transforaminal Epidural Steroid Injection in Chronic Lumbar Disc Herniation-Related Low Back and Radicular Pain","Comparison of the Effectiveness of High-Intensity Laser Therapy and Transforaminal Epidural Steroid Injection in Patients With Chronic Axial and Radicular Low Back Pain Due to Lumbar Disc Herniation: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of lumbar disc herniation confirmed by clinical examination and lumbar magnetic resonance imaging\n* Chronic axial low back pain and radicular pain related to lumbar disc herniation\n* Low back and\u002For radicular pain lasting longer than 3 months\n* Resting low back and\u002For radicular pain intensity of ≥5 on a 0-10 visual analog scale\n* Willingness to participate in the study and provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or suspected pregnancy\n* Presence of a cardiac pacemaker\n* History of epilepsy\n* Active or previous malignancy\n* History of spinal surgery\n* Uncontrolled systemic or psychiatric disease\n* Cauda equina syndrome or progressive neurological deficit\n* Peripheral neuropathy, including diabetic or alcohol-related neuropathy\n* Neurodegenerative disease\n* Acute trauma\n* Active systemic infection\n* Local infection or skin disease at the injection site or treatment area\n* Body mass index greater than 40 kg\u002Fm²\n* Bleeding disorder that contraindicates treatment\n* Spinal stenosis, spondylolysis, or spondylolisthesis\n* Neurogenic bladder or bowel syndrome\n* Rheumatologic disease\n* Arterial vascular disease or vascular claudication\n* Receipt of other physical therapy modalities within the last 3 months\n* Receipt of spinal injection therapy within the last 3 months\n* History of allergy to injection agents",{"count":533,"type":21},24,[100],"This prospective, randomized, single-blinded, controlled clinical trial aims to compare the effectiveness of high-intensity laser therapy and fluoroscopy-guided transforaminal epidural steroid injection in patients with chronic low back pain and lumbar radiculopathy. Eligible patients will be randomized into two parallel groups. One group will receive high-intensity laser therapy, and the other group will receive transforaminal epidural steroid injection. All participants will also receive a standardized home-based exercise program. Outcomes will be assessed at baseline, 2 weeks, 6 weeks, and 12 weeks after treatment. The primary outcome will be pain intensity measured by the Visual Analog Scale. Secondary outcomes will include functional disability, neuropathic pain symptoms, quality of life, and functional walking capacity.",[537,25,538,539],"Lumbar Disc Herniation","Radicular Pain","Lumbar Radiculopathy",[541,542,543,232,544,545,546,547],"High-intensity laser therapy","Transforaminal epidural steroid injection","Lumbar disc herniation","Radicular pain","Lumbar radiculopathy","Visual analog scale","Oswestry Disability Index","2026-06-30",{"date":550,"type":31},"2026-07-07",{"date":552,"type":31},"2025-08-01",{"date":554,"type":21},"2026-10-01",{"name":556,"class":38},"Ankara City Hospital Bilkent",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":98,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":39},"100524243","integrative-mindfulness-based-predictive-approach-for-chronic-low-back-pain-treatment-100524243","NCT06106191","Integrative Mindfulness-Based Predictive Approach for Chronic Low Back Pain Treatment","IMPACT","Inclusion Criteria:\n\n* Chronic low back pain, which is pain that persists for at least 3-months and has resulted in pain on at least half the days in the past 6 months\n* Willing and able to provide online or telephone informed consent\n* Speak English as the intervention manual is currently written in English\n\nExclusion Criteria:\n\n* Red flags- recent (past month) worsening of pain, unexplained fever, unexplained weight loss\n* Pregnancy\n* Metastatic cancer\n* Not a patient at a participating clinic or persons not planning to continue as a patient at a participating clinic for 6 or more months",{"count":565,"type":21},350,[100],"This study will identify unique signatures that people have which can cause pain by evaluating biological, psychological, and social markers using artificial intelligence. These markers can be used to accurately predict the response of diverse individuals with chronic low back pain (cLBP) to Mindfulness-Based Stress Reduction. This will help enhance clinician decision-making and the targeted treatment of chronic pain.\n\nThe overall objective is to use a unique machine learning (ML) approach to determine the biomarker signature of persons undergoing mindfulness based stress reduction (MBSR) treatment for their chronic low back pain (cLBP). This signature will facilitate clinical prediction and monitoring of patient response to MBSR treatment.\n\nThe design of the study is a single-arm clinical trial of the evidence-based MBSR program for patients with cLBP.",[131],[570,571,572,573,574,575,404],"Mindfulness based stress reduction (MBSR)","Machine learning (ML)","Biopsychosocial data","PEG (Pain, Enjoyment, General activity)","Pain interference","Pain intensity","2026-06-29",{"date":548,"type":31},{"date":579,"type":31},"2024-07-25",{"date":581,"type":21},"2029-12",{"name":583,"class":38},"Boston Medical Center",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":16,"minAge":592,"maxAge":593,"enrollmentInfo":594,"targetDuration":4,"studyType":98,"phases":596,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":39},"100645347","auricular-vagus-nerve-stimulation-in-patients-with-high-impact-chronic-low-back-pain-100645347","NCT07681336","Auricular Vagus Nerve Stimulation in Patients With High Impact Chronic Low Back Pain","Auricular Vagus Nerve Stimulation in Patients With High Impact Chronic Low Back Pain - a Prospective, Interventional, Open, Randomized, Controlled, Single-center Trial","VIVO","Inclusion Criteria:\n\n* Male or female patients aged ≥ 30 and ≤ 60 years;\n* High impact lumbar or lumbosacral myofascial\u002Fmusculoskeletal chronic (\\> 6 months) low back pain that is moderate to severe (defined as average pain over the last 4 weeks ≥ 5 on the NRS at baseline);\n* Normal function of lumbosacral nerves based on clinical assessment;\n* Unresponsive\u002Fintolerance (meaning insufficient pain reduction or intolerance) to oral pharmacotherapy (World Health Organization (WHO) grade II);\n* ODI 21-80 at baseline;\n* Patient understands the therapy and procedures, agrees to its provisions, and gives written informed consent prior to any procedures\n\nExclusion Criteria:\n\n* Organic low back pain (trauma, fracture, tumor, infection, documented severe degenerative spine, documented high-grade spinal stenosis, rheumatologic conditions);\n* Indication for back surgery;\n* Radicular pain;\n* New analgesics 2 weeks before baseline (paracetamol, NSAIDs, etc.);\n* Opioid analgesic therapy;\n* Underwent other physical therapy modalities, including TENS, ultrasound, infiltration, RF-treatment, 2 weeks before screening;\n* History of Vagus Nerve Stimulation or ear stimulation;\n* History of vasovagal syncope;\n* BMI \\> 35 kg\u002Fm² (Obesity Class 2 or higher);\n* Hemophilia;\n* Documented autonomic disorders;\n* Advanced stage or poorly controlled diabetes mellitus type I or II\n* Poorly controlled high blood pressure at baseline (systolic blood pressure (SBP) \\> 160 mmHg);\n* Major psychiatric comorbidity (HADS ≥ 10 on each subscale at baseline);\n* Other serious clinically relevant co-morbidity, florid malignant conditions or neurological diseases;\n* History of arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies;\n* Use of prescription blood thinners, e.g., oral anticoagulants (marevan, sintrom, marcoumar), noval oral anticoagulants (pradaxa, xarelto, eliquis, lixiana), anti-platelet medication (asaflow);\n* Infection, eczema, or psoriasis at application site (ear and neck);\n* Numbed and desensitized skin at the application site (ear and neck);\n* Serious drug-related behavioral issues (e.g., alcohol dependency, illegal substance abuse) in the last 6 months;\n* Pregnant, parturient or breast-feeding women;\n* Active implantable device (e.g. cardiac pacemaker, defibrillator, cochlear implant, neurostimulator like Spinal Cord Stimulation or Peripheral Nerve Stimulation) ;\n* Currently participating in another interventional clinical trial or participated over the last 3 months;\n* Patients who are unable to sufficiently speak and write in the Dutch language;\n* Mental and physical impairments that represent a source of risk for handling the device;\n* Patients under legal protection (curatorship, guardianship);\n* Patients subject to a legal protection measure;\n* An adult who is incapable or unable to give consent.","30 Years","60 Years",{"count":595,"type":21},44,[100],"The goal of this clinical trial is to evaluate whether auricular vagus nerve stimulation using the VIVO® device can improve function and reduce pain in adults with high-impact chronic low back pain when added to standard medical care. It will also assess the safety and usability of this therapy.\n\nThe study includes adult patients aged 30 to 55 years who have had moderate to severe chronic low back pain for more than 6 months and who did not experience sufficient relief with standard pain treatments.\n\nThe main questions this study aims to answer are:\n\n* Does adding the VIVO® device to standard care help people function better in daily life?\n* Does the VIVO® device help lower pain and improve wellbeing, sleep, and quality of life?\n\nResearchers will compare standard care plus VIVO® to standard care alone to see if the device improves outcomes.\n\nStandard care may include medication, physiotherapy, or other usual treatments.\n\nThe main outcome is the change in disability (measured using the Oswestry Disability Index) after 6 weeks of treatment.\n\nParticipants will:\n\n* Attend a baseline visit where medical history, physical examination, and questionnaires about pain, function, mood, sleep, and quality of life are collected;\n* Be randomly assigned to one of the two treatment groups;\n* Attend weekly visits for 6 weeks during the treatment phase;\n* Keep a diary of their pain levels and any treatments or medications used;\n* Complete questionnaires about pain, function, sleep, and wellbeing during the study.\n\nParticipants in the intervention group will:\n\nReceive a VIVO® wearable device applied to the ear, which delivers electrical stimulation to the vagus nerve; Use the device continuously over 6 weeks, with weekly replacement and adjustment of stimulation settings; Be able to adjust the stimulation intensity themselves using a handheld device.\n\nAfter the treatment period, all participants will be followed for 12 months, with additional visits or contacts to assess long-term effects, safety, and sustainability of the treatment.",[25],[600,601],"auricular vagus nerve stimulation","VIVO device","2026-06-26",{"date":604,"type":31},"2026-07-02",{"date":606,"type":31},"2026-03-04",{"date":608,"type":21},"2028-09",{"name":610,"class":38},"Algemeen Ziekenhuis Maria Middelares",{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":124,"enrollmentInfo":618,"targetDuration":4,"studyType":98,"phases":620,"briefSummary":621,"conditions":622,"keywords":629,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":141},"100465768","high-frequency-rf-current-effects-on-muscle-pain-and-function-100465768","NCT05345015","High Frequency RF Current Effects on Muscle Pain and Function","Acute and Chronic Effects of High Frequency RF Electrical Current on Pain and Muscle Function in Individuals With Musculoskeletal Pain","Individuals with Muscle Injury\n\nInclusion Criteria:\n\n* Age over 18 years.\n* Athletes: amateur soccer players or sprinters with regular, systematic training.\n* Suspected Grade I or II hamstring strain.\n* Cessation of training due to injury.\n* No surgical intervention in the previous year (for initial assessment as potential participants).\n\nExclusion Criteria:\n\n* History of injury to the same muscle (ipsilateral side) within the last 6 months.\n* Other injury to the posterior aspect of the thigh.\n* Other injuries or chronic pain in the trunk or lower limbs.\n* Use of non-steroidal anti-inflammatory drugs (NSAIDs) in the 3 months prior to the injury.\n\nIndividuals with Acute Low Back Pain\n\nInclusion Criteria:\n\n* Age over 18 years.\n* Pain located between the lower ribs and the gluteal folds (top of the buttocks).\n* Pain occurred on fewer than half of the days over the preceding six months.\n* Pain intensity $\\\\ge$ 6\u002F10 on the Visual Analogue Scale (VAS).\n* Pain related to one or more of the following:\n\n  * Lumbar facet joints\n  * Sacroiliac joints\n  * Lumbar intervertebral discs\n  * Muscles, tendons, or ligaments of the lumbar and sacral region\n  * Other bony structures of the lumbar spine\n* Discontinuation of non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics:\n\n  * 1 day prior to measurement\n  * 48 hours after measurement\n\nExclusion Criteria:\n\n* Radiographic evidence of inflammatory disease affecting the spine.\n* Spinal fracture.\n* Significant genetic structural abnormality of the spine.\n* Pregnancy.\n* Psychiatric disorders.\n* Receipt of systemic medication or treatment in the last 3 months.\n* Presence of neurological deficits (sensory, motor, or reflexes).\n* Receipt of TENS or TECAR therapy within the last year.\n\nIndividuals with Chronic Low Back Pain\n\nInclusion Criteria:\n\n* Episodes of low back pain (between the lower rib margin and the gluteal fold) for at least half of the days during the last 6 months.\n* Pain intensity $\\\\ge$ 20% on the Visual Analogue Scale (VAS).\n\nExclusion Criteria:\n\n* Spinal stenosis.\n* Radiographic evidence of inflammatory disease affecting the spine.\n* Vertebral fracture.\n* Presence of spondylolisthesis or spondylolytic lesion (spondylolysis).\n* Significant genetic structural abnormality of the spine.\n* Daily, severe low back pain.\n* Pregnancy.\n* Use of medications that might influence heart rate or blood pressure.\n* Psychiatric disorders.",{"count":619,"type":21},200,[100],"The purpose of this study is to examine the acute and chronic effects of high frequency electrical current transfer (frequently called \"TECAR\") on pain and functional movement in individuals with a musculoskeletal injury or pain. The participants will be assigned into an experimental or a control group and outcome measures will be measured prior to, after, 24 and 48 hours following a single intervention session (Acute effects) as well as 3 and 6 months after the intervention (chronic effects).",[623,131,624,625,626,627,628],"Transcutaneous Electric Nerve Stimulation","Hamstring Injury","Muscle; Injury, Quadriceps (Thigh)","Physical Therapy","Calf Muscle Pulled","Acute Low Back Pain",[630,631,632,633],"Sport injuries","TECAR therapy","Low back pain","Muscle injury","2026-06-23",{"date":602,"type":31},{"date":637,"type":31},"2022-09-01",{"date":639,"type":21},"2029-12-31",{"name":641,"class":38},"Aristotle University Of Thessaloniki",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":98,"phases":652,"briefSummary":654,"conditions":655,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":666},"100515037","phase-2-a-master-protocol-study-ly900028-of-multiple-intervention-specific-appendices-isas-in-participants-with-chronic-pain-100515037","NCT05986292","A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain","A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain","CPMP","Inclusion Criteria:\n\n* have a visual analog scale (VAS) pain value \\>40 and \\\u003C95 at screening and prerandomization screening.\n* have a history of daily pain for at least 12 weeks based on participant report or medical history\n* have a value of ≤30 on the pain catastrophizing scale\n* have a body mass index \\\u003C40 kilogram\u002Fsquare meter (kg\u002Fm²) (inclusive)\n* are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.\n* are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study\n\nExclusion Criteria:\n\n* have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia\n* have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)\n* have surgery planned during the study for any reason, related or not to the disease state under evaluation.\n* have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.\n* have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.\n* have fibromyalgia\n* have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)\n* have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.\n* have a positive human immunodeficiency virus (HIV) test result at screening\n* have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.",{"count":651,"type":21},10000,[653],"PHASE2","The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.",[656,657,131],"Osteoarthritis, Knee","Diabetic Neuropathic Pain","2026-06-19",{"date":634,"type":31},{"date":661,"type":31},"2020-01-30",{"date":663,"type":21},"2027-04",{"name":665,"class":270},"Eli Lilly and Company",64]